- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04572906
Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries
Phase 2a, Multicenter, Randomized, Patient and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to SOC in the Treatment of Acute Single Transected Peripheral Nerve Injury Occurring Below the Distal Border of the Brachial Plexus Requiring Surgical Repair.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
NTX-001 (Product) is a surgical product that consists of an active solution (drug), an isolation chamber medical device (chamber or device) and two (2) other sterile solutions.
NTX-001 has been developed as a surgical product to be used in conjunction with standard suture neurorrhaphy of a severed nerve. Use of NTX-001 is intended to safely accelerate the often slow and diminished return of function in repaired nerves. It often takes months and/or years to determine if function will be restored. By that point, restoration is often incomplete and can result in lifelong motor and/or sensory deficits. By reconnecting (PEG-fusion) a substantial number of axons within a severed nerve, the degeneration-regeneration cycle and subsequent atrophy may be reduced or even prevented for those axons and their targets, respectively. NTX-001 (PEG-fusion) has the potential to avoid the consequences of protracted denervation of distal target tissues by eliminating the period of total denervation thus reducing the time to stable recovery and providing greater innervation to affected tissues.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Vicki J Abbas, BSN RN
- Phone Number: 303-263-4646
- Email: vicki.abbas@neuraptive.com
Study Contact Backup
- Name: Seth Schulman, MD
- Phone Number: 617-416-4520
- Email: seth.schulman@neuraptive.com
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32607
- UF Health - University of FL - Gainesville
-
Orlando, Florida, United States, 32806
- Orlando Health
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Indiana Hand to Shoulder Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins Bayview Medical Center
-
Baltimore, Maryland, United States, 21218
- Curtis National Hand Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
Ohio
-
Columbus, Ohio, United States, 43202
- The Ohio State University Wexner Medical Center Hand and Upper Extremity Center
-
-
Virginia
-
Richmond, Virginia, United States, 23398
- Virginia Commonwealth University
-
-
Washington
-
Seattle, Washington, United States, 98107
- Harborview Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The subject is at least 12 years of age and not older than 80.
- The subject has sustained a confirmed (intra-op assessment) single transected peripheral nerve injury.
- The subject's nerve injury is classified as Sunderland's Fourth and Fifth Degree (Class III)
- The subject's nerve injury is amenable to minimal or acceptable tension, in direct, end-to-end repair.
- The surgical repair will occur within 48 hours of injury.
Exclusion Criteria:
- The subject has a PNI with a segmental loss (gap) that cannot be repaired with minimal or acceptable tension.
- Other treatments known to affect the growth and/or physiology of the neural and vascular system.
- The nerve injury has vascular damage that cannot be repaired to provide adequate perfusion of the injured site.
- The subject is pregnant and/or is breastfeeding.
- The subject has a significant medical comorbidity precluding immediate repair.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NTX-001
NTX-001 used during surgical repair of an upper extremity peripheral nerve injury in conjuction with standard suture neurorrhaphy.
|
One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy.
An isolation chamber medical device (device) is utilized to focus the application of PEG (Solution #2) on the coapted nerve for the required amount of exposure time.
Other Names:
|
No Intervention: Standard of Care
standard suture neurorrhaphy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events
Time Frame: Up to 48 Weeks
|
An adverse event is any untoward, undesired, or unplanned event in the form of signs, symptoms, disease, or laboratory or physiologic observations occurring in a person given a study product or in a clinical study.
A treatment-emergent adverse event was defined as any adverse event that newly appeared, increased in frequency, or worsened in severity on or after the exposure to the study product.
|
Up to 48 Weeks
|
Michigan Hand Questionnaire Total Score (MHQ)
Time Frame: Week 12
|
The MHQ measures hand function and is scored from 0-100; with 100 being the "best" score.
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Numeric Pain Rating Scale (NPRS)
Time Frame: Weeks 4, 8, 12, 24, 36 and 48
|
The NPRS measures pain intensity on a scale from 0 representing no pain and 10 to the worst pain as bad as you can imagine.
|
Weeks 4, 8, 12, 24, 36 and 48
|
Modified British Medical Research Council (MMRC) sensory grading (S0-S4)
Time Frame: Weeks 4, 8, 12, 24, 36 and 48
|
The SWMT measures sensation as using a score from S0 to S4; higher score indicates better sensation.
|
Weeks 4, 8, 12, 24, 36 and 48
|
Modified British Medical Research Council (MMRC) motor grading (M0-M5)
Time Frame: Weeks 4, 8, 12, 24, 36 and 48
|
The MRCC motor measures the function of the muscles; on a scale from M0 to M5; the higher score indicates better strength.
|
Weeks 4, 8, 12, 24, 36 and 48
|
Semmes-Weinstein Monofilament Test (SWMT)
Time Frame: Weeks 4, 8, 12, 24, 36 and 48
|
The SWMT assesses sensation using using equipment that measures force felt in grams.
|
Weeks 4, 8, 12, 24, 36 and 48
|
Pinch Strength
Time Frame: Weeks 4, 8, 12, 24, 36 and 48
|
The Pinch test assesses strength using using equipment that measures strength in pounds.
|
Weeks 4, 8, 12, 24, 36 and 48
|
Grip Strength
Time Frame: Weeks 4, 8, 12, 24, 36 and 48
|
The Grip test assesses strength using using equipment that measures strength in pounds.
|
Weeks 4, 8, 12, 24, 36 and 48
|
Cold Intolerance Symptom Severity (CISS)
Time Frame: Weeks 4, 8, 12, 24 and 48
|
The CISS focuses on the impact of cold intolerance on activities of daily life; the score ranges a score between 0 and 10, where 0 is no symptoms at all and 100 is the most severe symptoms you can possibly imagine.
|
Weeks 4, 8, 12, 24 and 48
|
Patient Global Impression of Change (PGIC)
Time Frame: Weeks 4, 8, 12, 24 and 48
|
The PGIC measures information about the effect of a treatment intervention in an individual subject, scored 0 to 7; with 0 being the worst and 7 being the best.
|
Weeks 4, 8, 12, 24 and 48
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Seth Schulman, MD, Neuraptive Therapeutics Inc.
Publications and helpful links
General Publications
- Ghergherehchi CL, Mikesh M, Sengelaub DR, Jackson DM, Smith T, Nguyen J, Shores JT, Bittner GD. Polyethylene glycol (PEG) and other bioactive solutions with neurorrhaphy for rapid and dramatic repair of peripheral nerve lesions by PEG-fusion. J Neurosci Methods. 2019 Feb 15;314:1-12. doi: 10.1016/j.jneumeth.2018.12.015. Epub 2018 Dec 23.
- Mikesh M, Ghergherehchi CL, Louis Hastings R, Ali A, Rahesh S, Jagannath K, Sengelaub DR, Trevino RC, Jackson DM, Bittner GD. Corrigendum to "Polyethylene glycol solutions rapidly restore and maintain axonal continuity, neuromuscular structures, and behaviors lost after sciatic nerve transections in female rats.". J Neurosci Res. 2018 Sep;96(9):1623. doi: 10.1002/jnr.24277. No abstract available.
- Mikesh M, Ghergherehchi CL, Rahesh S, Jagannath K, Ali A, Sengelaub DR, Trevino RC, Jackson DM, Tucker HO, Bittner GD. Corrigendum to "Polyethylene glycol treated allografts not tissue matched nor immunosuppressed rapidly repair sciatic nerve gaps, maintain neuromuscular functions, and restore voluntary behaviors in female rats". J Neurosci Res. 2018 Sep;96(9):1624. doi: 10.1002/jnr.24278. No abstract available.
- Bittner GD, Spaeth CS, Poon AD, Burgess ZS, McGill CH. Repair of traumatic plasmalemmal damage to neurons and other eukaryotic cells. Neural Regen Res. 2016 Jul;11(7):1033-42. doi: 10.4103/1673-5374.187019.
- Bittner GD, Sengelaub DR, Trevino RC, Peduzzi JD, Mikesh M, Ghergherehchi CL, Schallert T, Thayer WP. The curious ability of polyethylene glycol fusion technologies to restore lost behaviors after nerve severance. J Neurosci Res. 2016 Mar;94(3):207-30. doi: 10.1002/jnr.23685. Epub 2015 Nov 3.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NTx20201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Nerve Injuries
-
Silk Biomaterials srlUnknownPeripheral Nerve Injury Digital Nerve HandSwitzerland
-
University Hospital, Basel, SwitzerlandCompletedPeripheral Nerve Injury Digital Nerve Hand LeftSwitzerland
-
Major Extremity Trauma Research ConsortiumActive, not recruitingPeripheral Nerve Injury(Ies)United States
-
University of Sao PauloConselho Nacional de Desenvolvimento Científico e TecnológicoCompletedMedian Nerve Disease | Ulnar Nerve Disease | Peripheral Nerve DiseaseBrazil
-
BG Trauma Center TuebingenCompletedPeripheral Nerve Injury Upper Limb
-
Brooke Army Medical CenterWalter Reed National Military Medical Center; Curtis National Hand Center at... and other collaboratorsUnknown
-
Washington University School of MedicineNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingHealthy | Peripheral Nerve Injury Upper LimbUnited States
-
Lund University HospitalRecruitingNerve Injury | Peripheral Nerve InjuriesSweden
-
Checkpoint Surgical Inc.Congressionally Directed Medical Research ProgramsRecruitingNerve Injury | Peripheral Nerve Injuries | Nerve Palsy | Peripheral Nerve Injury Upper LimbUnited States
-
Kocaeli UniversityCompletedPeripheral Nerve Injury, Virtual Reality, RehabilitationTurkey
Clinical Trials on NTX-001
-
Major Extremity Trauma Research ConsortiumUnited States Department of DefenseRecruitingPeripheral Nerve InjuriesUnited States
-
Neuraptive Therapeutics Inc.Temporarily not availablePeripheral Nerve Transections, Acute or Planned in Upper Extremity and Facial NervesUnited States
-
Neuraptive Therapeutics Inc.TerminatedFacial ParalysisUnited States
-
University of Alabama at BirminghamRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic LeukemiaUnited States
-
Alkermes, Inc.Completed
-
Pinotbio, Inc.CompletedHealthy VolunteersKorea, Republic of
-
Toll Biotech Co. Ltd. (Beijing)Recruiting
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States
-
IntegoGen, LLCWithdrawnHidradenitis SuppurativaUnited States
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina